Vidac Pharma Holding Plc: Research Initiation by Sphene Capital GmbH with a Buy Rating

Sphene Capital GmbH has initiated coverage of Vidac Pharma Holding Plc with a "Buy" rating and set a price target of EUR 4.90. The target price reflects the expected approval of Vidac Pharma's core product, VDA-1102-AK. The valuation is based on a three-stage discounted cash flow model and a Monte Carlo analysis, estimating equity values between EUR 4.04 and EUR 5.40 per share. An economic profit model suggests values up to EUR 6.50 per share, indicating a solid long-term investment potential.

Established in 2012 by Dr. Max Herzberg, Vidac Pharma is a clinical-stage biopharmaceutical firm focusing on oncology and oncodermatology therapies. Its treatments aim to reverse cancer cells' abnormal metabolism. Specifically, Vidac's research targets the overexpression of hexokinase 2 (HK2) in cancer cells, modifying its binding to mitochondria to reduce glycolysis and induce apoptosis, sparing normal cells.

Currently, Vidac Pharma is developing two drugs. VDA-1102, in Phase 2 trials, targets actinic keratosis and cutaneous T-cell lymphoma. VDA-1275, in preclinical development, aims to treat solid tumors systemically. These advancements underscore Vidac's commitment to innovative cancer treatments.